Dr Dejan Juric speaks to ecancer at ASCO 2024 about additional analysis from a study evaluating first-line inavolisib/placebo plus palbociclib plus fulvestrant (Inavo/pbo plus palbo plus fulv) in patients with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion.

He explains that from data from patient reported outcomes showed that there was a significant delay in deterioration of their pain with this triple combination.

Dr Juric also reports that the quality of life and day to day function is maintained with this combination when compared to the placebo arm.